100. VITRO BIOPHARMA: www.vitrodiag.com

We develop stem cell technology for potential use in diabetes research and treatment. Our research has led to a patent-pending method for generation of adult stem cells from cells isolated from tissues. While embryonic stem cells are capable of differentiation into all of the various cells of the body, adult stem cells are more limited in differentiation capacity generally including the cell types that comprise the tissue of origin. Adult stem cells are now used for transplantation therapy of blood disorders, e.g., leukemia. Our present focus is on the application of adult stem cells to therapeutic replacement of endocrine organs that produce hormones essential to physiological regulation of the body. While use of embryonic stem cells involves controversial ethical issues and complex differentiation procedures, we use tissue-derived adult stem cell lines with demonstrated differentiation capacity for our research. In addition to treatment of diabetes, our novel stem cell generation technology may provide therapeutic options to other diseases or conditions resulting from death or degeneration of specific cells including, for example, age-related hearing loss, macular degeneration, muscular dystrophy, heart attack, and congestive heart failure, Parkinson’s disease, etc.

The Company has generated 29 adult human pancreatic stem cell lines that are distinct from the limited number of embryonic stem cell lines that are presently approved for federally funded research. Some of these lines have been extensively expanded in cell culture and have demonstrated self-renewal properties by growth through 100 to 200 population doublings (PD) while mortal cells typically do not expand beyond 50 population doublings. Also, we have developed methods of differentiation that result in expression of biomarkers characteristic of alpha and beta cells suggesting that the cell lines have at least multipotent differentiation capacity. Some markers of non-pancreatic cell lineage are expressed in these cells raising the possibility of differentiation into other cell types. We manufacture select human cell lines and related products according to GMP standards for use in stem cell and drug discovery research. Our research products include two human cell lines of pancreatic origin and supporting products including optimized growth and cryopreservation media. These lines are Mesenchymal, attachment-dependent cells that exhibit properties of human Mesenchymal stem cells, affording researchers several unique opportunities.

Vitro Diagnostics, Inc.
12635 E. Montview Blvd.
Suite 218
Aurora, CO 80045
Phone (720) 859-4120
Fax (720) 859-4110
Email: Jim@Vitrodiag.com

99. VISTAGEN THERAPEUTICS: www.vistagen-inc.com

VistaGen Therapeutics is a biopharmaceutical company pioneering the use of embryonic stem (ES) cells for drug discovery and development.

Proprietary ES Cell Platform

VistaGen's core R&D platform consists of novel and clinically-relevant human and animal ES cell technologies and associated bioinformatics systems. Our technologies enable the discovery and validation of disease- and pathway-specific proteins that are biological drugs and classical drug targets. VistaGen's novel ES cell biological systems are the basis for innovative custom pharmacology and toxicology screening systems. We believe that the stem cell systems will enable the identification of drug candidates with greater efficiency and higher probability of success compared to traditional approaches. With VistaGen's ES cell technologies, researchers utilize proprietary cell lines and customized differentiation protocols to create a wide range of clinically relevant cells at higher efficiency and purity than the Company's competitors. This is especially relevant for insulin-producing b-islet cells, dopamine-positive neurons, and cells of the heart, liver, blood and vascular organs.

Toxicity Screening Tools

VistaGen's ES cell technologies provide human ES cell-based heart and liver cell systems that address the limitations of current biological systems and focus on the two most relevant cell types for toxicity testing. Additionally, VistaGen's ES cell technologies will enable researchers to assess how genetic differences of people could affect responses to new drugs. VistaGen's ES cell toxicology screening systems could also potentially reduce the number of animals used in drug development.

AV-101

VistaGen's lead drug candidate, AV-101, is a potential first-in-class "GlyB site" antagonist of the NMDA-receptor, entering Phase 1 clinical development for epilepsy and neuropathic pain markets. AV-101 is expected to address the limitations of previous NMDA-receptor antagonists by providing high efficacy and expected low adverse side effects. AV-101 will potentially prevent or delay the onset and reduce the severity of epileptic seizures. Concurrently, AV-101 minimizes neural toxicity that accompanies the pathological activation of NMDA-receptors, which are associated with seizures, inflammation and brain damage. In addition, NMDA-receptors are active in animal models of chronic pain that is typically associated with diabetic, viral and inflammatory neuropathies. Human Resources at: hr@vistagen.com

98. VIACELL: www.viacellinc.com

ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, diabetes and fertility. ViaCell is seeking imaginative thinkers who are ready for an exciting, entrepreneurial environment, who thrive in a fast-paced workplace and who want to contribute to a highly motivated, success-driven team. When you chose a career with ViaCell, you won’t just be making a difference – you’ll be creating one. ViaCell offers competitive compensation and benefits programs. ViaCell is an equal opportunity employer. If you have any questions about career opportunities at ViaCell, please contact ViaCell human resources at careers@viacellinc.com.

Marc D. Beer, President and Chief Executive Officer

245 First St,

Cambridge,

MA 02142

97. VET-STEM: www.vet-stem.com

Who is Vet-Stem?
The founders of Vet-Stem have more than 20 years of experience in development and testing of human and veterinary pharmaceuticals as well as production and processing of sterile biological samples. Previous companies (HTI Bio-Services and HTI Bio-Products, among others) have grown to over $15 million in sales with more than 200 employees and have been listed among the Inc. 500 fastest growing companies in the U.S.



Vet-Stem management has experience in laboratory automation, biologic product development and licensing, FDA compliance, and veterinary practice management. The experienced Vet-Stem team is capable of providing high-quality services and products and responding to the needs of the veterinary community.

Mission Statement
Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine technology to the veterinary profession. Our goal is to be the conduit for the latest developments in human medical technology and provide easy-to-use services and products to the practicing veterinarian.

Investor Inquiries
Vet-Stem is a privately held company with a portfolio of intellectual property centered around Regenerative Veterinary Medicine. Interested private investors may call or email to inquire about current investment opportunities.

Vet-Stem
12860 Danielson Court, Suite B
Poway, CA 92064

Phone:
1-88-VET-STEM-1 or
888-387-8361
858-748-2004

Fax: 858-748-2005

info@vet-stem.com

96. VESTA THERAPEUTICS: www.vestatherapeutics.com

Vesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation. Clinicians in academic settings have found that, following administration, human hepatocytes engraft and create new functioning liver tissue, which may provide a bridge to transplant or in some cases, eliminate the need for a liver transplant. The Food and Drug Administration has allowed the Company's Investigational New Drug (IND) application for a Phase I clinical trial of cryopreserved, allogeneic human liver cells for the treatment of patients with cirrhosis and end-stage liver disease.

Vesta is an equal opportunity employer. Vesta is committed to equal employment opportunities in all employment practices and decisions including recruitment, hiring, promotion, training, compensation, and disciplinary action. Vesta does not discriminate on the basis of race, religion, national origin, color, age, sex, disability, veteran status, sexual orientation, genetic information, or any other legally protected characteristic. Employees are our most valuable resource. We are committed to fostering an environment where recognition, innovation, communication, and an entrepreneurial spirit are encouraged and rewarded. We attract and retain qualified candidates by providing competitive cash compensation and benefits packages. It is the Company's policy to provide employees with opportunities to develop professionally by providing them with tuition reimbursement and the opportunity to attend professional conferences.

94. TRISTEM: http://www.tristemcorp.com/

The TriStem Group has been set up by Mr.Ghazi Dhoot and Dr. Ilham Saleh Abuljadayel to further research and develop its retrodifferentiation technology which is used to create stem cells from mature adult cells. The retrodifferentiation technology is based on the results of 12 years of research and currently TriStem is the only company that owns, and is in the process of commercialising, this technology. The main advantage of TriStem's new process over existing methods of harvesting stem cells is that it provides large quantities of stem cells which are by definition DNA matched and, therefore, bypasses the political and ethical issues concerned with therapeutic cloning.

TriStem believes that there is a wide ranging potential for clinical, pharmaceutical and biotechnological applications for its proprietary stem cell technology. For example, novel compounds could be screened for their retrodifferentiation ability in order to manipulate a specific cell type in the body and such cells can be studied for research purposes to better understand stem cell biology.

Stem cells are being investigated as therapeutics for a wide variety of applications. TriStem will initially evaluate the clinical potential of its retrodifferentiation stem cell technology in aplastic anaemia, thalassemia and leukaemia patients that would ordinarily require a blood marrow transplant (BMT). Leukaemia, a disease which resulted in an estimated 22,100 deaths in the United States alone in 1999, is also a disease area with a wide unmet clinical need and a large potential for expedited clinical development. TriStem will also in due course explore the application of its technology in other areas of oncology such as lymphoma, myeloma and solid tumours. In addition, the technology should over time be employed in the treatment of a much wider range of illnesses such as spinal cord injury, diabetes and heart disease.

Please contact us with any requests for further
information: info@tristemcorp.com

Or write to us
571, Finchley Road
Unit 320
London NW3 7BN
United Kingdom

93. TIGENIX: www.tigenix.com

TiGenix is a biomedical company operating at the cutting edge of regenerative medicine. Its core mission is to provide a comprehensive solution for damaged and osteoarthritic joints through the combination of innovative cellular therapies and locally delivered therapeutics. We are constantly on the lookout to strengthen our team. If you are interested and believe you can contribute to our success, don't hesitate to contact us at careers@tigenix.com.

The Company's first product, ChondroCelect, is an improved ACI product, the first to incorporate identity characterization based on in vivo biological function. Designed to guarantee formation of stable hyaline cartilage in vivo, ChondroCelect aims at true functional repair of the demaged joint surface.

Rebekka Declercq,

TiGenix,

Technologielaan 3,

3001 Leuven.

rebekka.declercq@tigenix.com

92. THERAVITAE: www.theravitae.com

TheraVitae is a multi-national healthcare company focused on using the patient’s own adult stem cells to treat a variety of disorders, especially cardiovascular diseases. We collaborate with eminent physicians and scientists who are affiliated with well-known medical and academic institutions. We are committed to make the benefits of adult stem cell therapy accessible to all with integrity, safety and compassion.

VesCell™ – Adult Stem Cell therapy for Heart Disease

Cardiologists and cardiac surgeons are using VesCell™ to treat no-option patients suffering from Ischemic Heart Disease (Coronary Artery Disease), Cardiomyopathy and End-stage Heart Failure by relieving debilitating symptoms such as severe angina pectoris (chest pain) and shortness of breath. Read More

VesCell™ – Adult Stem Cell Therapy for PAD (Peripheral Artery Disease)

VesCell™ PAD is the latest adult stem cell technology developed by TheraVitae. It is using patients’ stem cells to treat severe disease of the lower limbs, enriching blood flow to the affected area and thus avoiding possible amputation.

Israel Office:

7 Pinhas Sapir Street
P.O. Box 4049,
Ness Ziona 74140,
Israel

Tel: + (972) 8940-9170
Fax: + (972) 8940-9167

Thailand Office:

36/72 PS Tower, 21st Floor,
Sukhumvit 21 Rd.
Klongtoey-Nua,Wattana,
Bangkok, Thailand 10110
E-Mail : enquiries@TheraVitae.com

USA Office:

1 Galleria Tower 13355 Noel, Suite 1700,
Dallas, Texas 75240, USA, Email:pr@TheraVitae.com

91. THERADIGM: www.theradigm.com

Theradigm, Inc., a portfolio company of Toucan Capital Fund II, is developing cell-based therapies for treatment of the central nervous system (CNS) disorders. Two different types of cells (1) neural stem cells and (2) bone marrow stromal cells may be applied alone or in combination to constitute unique therapies. Theradigm has a substantial intellectual property base covering use of these cells in CNS applications.

Theradigm, Inc. is an equal opportunity employer. Theradigm, Inc. is committed to equal employment opportunities in all employment practices and decisions including: recruitment, hiring, promotion, training, compensation, and disciplinary action with regard to the terms and conditions of employment. Theradigm, Inc. does not discriminate on the basis of race, religion, national origin, color, age, sex, disability, veteran status, sexual orientation, genetic information, or any other legally protected characteristic. Employees are our most valuable resource. We are committed to fostering an environment where recognition, innovation, communication, and an entrepreneurial spirit are encouraged and rewarded. We attract and retain qualified candidates by providing competitive cash compensation and benefits package. It is Theradigm's policy to provide employees with significant opportunities to develop professionally by providing them with tuition reimbursement and the opportunity to attend professional conferences.

Human Resources
1448 S. Rolling Road
Baltimore, MD 21227
hr@cognatetherapeutics.com

Smita Savant-Bhonsale
Vice President and General Manager ssavant@theradigm.com

Amanda Hendricks Human Resources
ahendricks@theradigm.com

Location

Theradigm, Inc. -East
1448 S. Rolling Road
Baltimore, MD 21227
(410) 455-5697 - Phone
(410) 455-5551 – Fax

90. THROMBOGENICS: www.thrombogenics.com

ThromboGenics Ltd is a privately held company founded in Dublin, Ireland in 1998, focused on discovery and development of biotherapeutics for treatment of vascular diseases (including cardiovascular, cerebrovascular and peripheral vascular disease). ThromboGenics' founder and CEO is Désiré Collen, M.D., Ph.D., a world-renowned expert in cardiovascular disease. Prof. Collen directs the Molecular and Cardiovascular Medicine Group at University of Leuven, Belgium, which provides much of the initial research for ThromboGenics programs. Professor Collen's laboratory was the first to produce clinical supply of tissue plasminogen activator (tPA), one of the most effective drugs for thrombolytic therapy of acute myocardial infarction (heart attack). This proprietary molecule is licensed to Genentech in return for royalties on worldwide sales.

Recently, our development of improved ES cell derivation methods, have generated us the possibility to derive ES cells from any mouse strain. These improved ES cell derivation methods even allow the derivation of ES cells from mice strains that were previously considered as non-permissive for ES cell derivation. All derived cell lines have proven germ-line transmission capability at high passage numbers. Among the future research aims of Thromb-X, are the derivation of embryonic stem cells from non-murine species (rabbit, rat, pig), the nuclear transfer technique to produce genetically modified rabbits, and the establishment of pronuclear injection in pigs.

If you are interested in applying to ThromboGenics, please contact us or send your resume to:

Karen Cauwels

ThromboGenics NV

Herestraat 49

B-3000 Leuven

Belgium

Tel: +32 (16) 34 61 94

Fax: +32 (16) 34 61 34

E-mail: karen.cauwels@thrombogenics.com

89. THERMOGENESIS: www.thermogenesis.com

ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics. The Company's technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company's BioArchive® System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour.

ThermoGenesis offers its fulltime employees a comprehensive benefits package which includes participation in a Section 125 Cafeteria plan, a 401(k) plan, vacation and sick leave, and ten paid holidays. ThermoGenesis is an Equal Opportunity Employer, welcoming individuals of diverse talents and backgrounds. Our Company promotes and supports a drug-free workplace. You are welcome to submit your resume to HR@ThermoGenesis.com if you feel an opening fits your profile. Our Human Resources team will review your resume and contact you if there is a match. Please, no phone calls.

ThermoGenesis Corp.
2711 Citrus Road
Rancho Cordova, CA 95742
USA

Toll free: 800-783-8357 (U.S.A./Canada)
Direct: (+1) 916-858-5100
Fax: (+1) 916-858-5199

Human Resources

hr@thermogenesis.com

88. TRANSITION THERAPEUTICS: www.transitiontherapeutics.com

Transition Therapeutics Inc. is a fully integrated biopharmaceutical company with a proprietary state-of-the art drug discovery engine and extensive drug development program exploring novel therapeutics in multiple disease indications. The focus of the corporate business is to discover and advance lead molecules to the most valuable and competitive targets in the industry using our state-of-the-art drug discovery engine, to accelerate the development of multiple products for large disease indications and to generate shareholder value through partnership with major pharmaceutical companies.

hr@transitiontherapeutics.com.